(Total Views: 261)
Posted On: 07/08/2018 2:40:34 PM
Post# of 72446
It just seems odd that a partnership only brings us to $3-4 after having been there over three years ago with only one phase 2 trial completed.
One would think that a modest B-OM deal: $20M upfront + trial costs + $200M milestones would immediately do the following:
1) Provide immediate balance sheet relief.
2) Provide immediate BP validation of the company and management.
3) Remove any ambiguity regarding the B-OM results (real or fabricated)
4) Provides a clear path to phase 3 on at least one indication.
I suppose sans a good Prurisol result and considering the millions of shares Aspire is holding along with the significantly larger share count $3-4 is probably more like $5-7 in 2014 terms - not terrible. Once we get the phase 3 started we'd probably get another milestone payment which would increase enthusiasm and hopefully permanently eliminate the Aspire factor.
I'm hoping we can uplist before Aspire starts clearing their shares. Institutional support will help absorb them pretty well.
One would think that a modest B-OM deal: $20M upfront + trial costs + $200M milestones would immediately do the following:
1) Provide immediate balance sheet relief.
2) Provide immediate BP validation of the company and management.
3) Remove any ambiguity regarding the B-OM results (real or fabricated)
4) Provides a clear path to phase 3 on at least one indication.
I suppose sans a good Prurisol result and considering the millions of shares Aspire is holding along with the significantly larger share count $3-4 is probably more like $5-7 in 2014 terms - not terrible. Once we get the phase 3 started we'd probably get another milestone payment which would increase enthusiasm and hopefully permanently eliminate the Aspire factor.
I'm hoping we can uplist before Aspire starts clearing their shares. Institutional support will help absorb them pretty well.
(1)
(0)
